An article in the journal Science (Volume 391, Number 6791, Pages 1210-1212, March 2026) states that there is not yet a proper schedule for marijuana under the Controlled Substances Act (CSA). The process of moving marijuana from Schedule I to Schedule III began in May 2024 with a proposed rule from the DEA that received nearly 43,000 comments. In August 2023, HHS recommended this transfer to DEA based on a scientific and medical review that confirmed accepted medically applicable potential for the treatment of disease-related anorexia, nausea, vomiting, and pain. On December 18, 2025, President Trump issued an Executive Order directing that rescheduling to Schedule III be expedited in accordance with the law. The move is intended to facilitate research into medical marijuana and CBD, including the use of real-world data for standards of care. Still, administrative steps such as public hearings remain outstanding, causing delays. Forty states and the District of Columbia have approved medical marijuana programs. Rescheduling would allow better access to full-spectrum CBD products for patients.[1][2][3][7]